FDA Approves Treg Cell Therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

  • By

  • Kathryn Wighton

  • July 1, 2026

  • 2 min

Share

  • 1

    The FDA approved Tregzi, the first regulatory T-cell-based immunotherapy for chronic graft-versus-host disease in blood cancer patients.

  • 2

    Tregzi is composed of donor-derived regulatory T cells and conventional T cells from an 8/8 HLA-matched donor.

  • 3

    The approval was based on the PRECISION-T trial, which included 187 adult patients with blood cancers.

  • 4

    One-year chronic GVHD-free survival was 78% with Tregzi, compared to 38% with standard stem cell transplant.

  • 5

    The most common side effects of Tregzi were infections, with no severe infusion reactions reported during the study.

Original Source(s)

FDA Approves Treg Cell Therapy

  • by Kathryn Wighton

  • July 1, 2026

Related Content

10 Growing US Metro Areas to Consider for Private Practice

These 10 metropolitan areas recorded population growth and had recently completed, ongoing, or announced health care infrastructure projects.

10 states that support physician work-life balance

These 10 states have paid family or medical leave programs and health, wellness, peer support, or monitoring resources available to physicians or other health professionals.

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.